Glenmark gets USFDA nod to sell generic blood pressure drug

Glenmark will commence distribution of trandolapril and verapamil hydrochloride tablets immediately

Press Trust of India New Delhi
Last Updated : Feb 26 2015 | 12:22 PM IST
Glenmark Pharmaceuticals today announced receipt of approval from the US health regulator to sell its generic version of AbbVie Inc's blood pressure drug Tarka in the American market.

The approval for trandolapril and verapamil hydrochloride extended release tablets has been granted to Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd.

Glenmark will commence distribution of trandolapril and verapamil hydrochloride tablets immediately. These will be available in strengths of 1mg/240mg, 2mg/180 mg, 2mg/240mg and 4mg/240 mg, the company said in a filing to the BSE.

Also Read

AbbVie Inc's Tarka is indicated for treatment of hypertension.

Citing IMS Health sales data, Glenmark said in the 12 months period ending December 2014, annual sales of Tarka stood at about $23.5 million.

Current portfolio of the company consists of 95 products authorised for distribution in the US and 74 ANDA's pending approval with the US health regulator, it added.

Shares of Glenmark Pharmaceuticals were trading at Rs 779.60 per scrip in the morning trade, down 1.15% from the previous close on the BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 26 2015 | 12:15 PM IST

Next Story